Insmed Sees Unusually Large Options Volume (NASDAQ:INSM)

Insmed Incorporated (NASDAQ:INSM) saw unusually large options trading on Thursday. Stock traders bought 11,548 call options on the stock. This is an increase of approximately 648% compared to the average volume of 1,544 call options.

Analysts Set New Price Targets

Several brokerages have weighed in on INSM. JPMorgan Chase & Co. lifted their target price on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Wells Fargo & Company lifted their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. Stifel Nicolaus cut their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. Morgan Stanley lifted their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Finally, Guggenheim reissued a “buy” rating and set a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

Insiders Place Their Bets

In other Insmed news, COO Roger Adsett sold 42,975 shares of Insmed stock in a transaction on Monday, February 10th. The shares were sold at an average price of $78.61, for a total value of $3,378,264.75. Following the transaction, the chief operating officer now directly owns 146,082 shares in the company, valued at approximately $11,483,506.02. The trade was a 22.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO William Lewis sold 6,830 shares of the stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total transaction of $479,192.80. Following the sale, the chief executive officer now owns 233,924 shares of the company’s stock, valued at $16,412,107.84. This trade represents a 2.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 471,797 shares of company stock valued at $37,621,239 over the last quarter. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Elequin Capital LP acquired a new position in shares of Insmed in the fourth quarter valued at approximately $28,000. Steward Partners Investment Advisory LLC lifted its stake in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. NBC Securities Inc. acquired a new stake in shares of Insmed during the first quarter worth $49,000. V Square Quantitative Management LLC increased its stake in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares during the last quarter. Finally, Spire Wealth Management purchased a new position in Insmed during the fourth quarter worth approximately $47,000.

Insmed Trading Down 2.6 %

Shares of INSM opened at $68.96 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed has a 1-year low of $21.92 and a 1-year high of $84.91. The stock has a market cap of $12.54 billion, a price-to-earnings ratio of -12.34 and a beta of 1.07. The firm has a 50 day simple moving average of $74.61 and a 200-day simple moving average of $73.55.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Equities analysts forecast that Insmed will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.